Mef2C is a lineage-restricted target of Scl/Tall and regulates megakaryopoiesis and B-cell homeostasis

Blood

Volumn 113, Issue 15, 2009, Pages 3461-3471

  Gekas, Christos ^a   Rhodes, Katrin E ^a   Gereige, Laurraine M ^a   Helgadottir, Hildur ^b   Ferrari, Roberto ^a   Kurdistani, Siavash K ^a   Montecino Rodriguez, Encarnacion ^a   Bassel Duby, Rhonda ^c   Olson, Eric ^c   Krivtsov, Andrei V ^b   Armstrong, Scott ^b   Orkin, Stuart H ^b,d,e   Pellegrini, Matteo ^a   Mikkola, Hanna K A ^a,f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e HARVARD STEM CELL INSTITUTE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; MYOCYTE ENHANCER FACTOR 2 C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; VAV PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; MEF2C PROTEIN, MOUSE; MYOGENIC FACTOR; ONCOPROTEIN; TAL1 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL HYBRIDIZATION; CELL LINE; CELL POPULATION; CELL SIZE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYO; ERYTHROID CELL; FETUS; FETUS LIVER; HOMEOSTASIS; IN VITRO STUDY; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREMATURE AGING; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; STEM CELL; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE SHAPE; ANIMAL; CELL LINEAGE; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEMATOPOIETIC STEM CELL; LIVER; LYMPHOPOIESIS; MALE; METABOLISM; PHYSIOLOGY; PREGNANCY; PRENATAL DEVELOPMENT; THROMBOCYTE; THROMBOCYTOPOIESIS;

ANIMALS; B-LYMPHOCYTES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOOD PLATELETS; CELL LINE, TRANSFORMED; CELL LINEAGE; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; LIVER; LYMPHOPOIESIS; MALE; MEGAKARYOCYTES; MICE; MYOGENIC REGULATORY FACTORS; PREGNANCY; PROTO-ONCOGENE PROTEINS; THROMBOPOIESIS; TRANSCRIPTION, GENETIC;

EID: 65149100673     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-167577     Document Type: Article

References (50)

1. Orkin SH, Zon LI. Hematopoiesis: an evolving para-digm for stem cell biology. Cell. 2008;132:631-644.
2. Mikkola HK, Orkin SH. The journey of developing hematopoietic stem cells. Development. 2006; 133:3733-3744.
3. Teitell MA, Mikkola HK. Transcriptional activa-tors, repressors, and epigenetic modifiers con-trolling hematopoietic stem cell development. Pediatr Res. 2006;59:33R-39R.
4. Orkin SH, Porcher C, FujiwaraY, Visvader J, Wang LC. Intersections between blood cell devel-opment and leukemia genes. Cancer Res. 1999; 59[suppl]:1784S-1787S; discussion 1788S.
5. Robertson SM, Kennedy M, Shannon JM, Keller G. A transitional stage in the commitment of mesoderm to hematopoiesis requiring the transcription factor SCL/tal-1. Development. 2000;127:2447-2459.
6. ElefantyAG, Robb L, Birner R, Begley CG. He- matopoietic-specific genes are not induced dur-ing in vitro differentiation of scl-null embryonic stem cells. Blood. 1997;90:1435-1447.
7. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukae-mia oncoprotein tal-1/SCL. Nature. 1995;373: 432-434.
8. Robb L, Elwood NJ, ElefantyAG, etal.Thescl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 1996;15:4123-4129.
9. Mikkola HK, Fujiwara Y, Schlaeger TM, Traver D, Orkin SH. Expression of CD41 marks the initia-tion of definitive hematopoiesis in the mouse em-bryo. Blood. 2003;101:508-516.
10. SchlaegerTM, Mikkola HK, Gekas C, Helgadottir HB, Orkin SH. Tie2Cre-mediated gene ablation defines the stem-cell leukemia gene (SCLAaH)- dependent window during hematopoietic stem- cell development. Blood. 2005;105:3871-3874.
11. Hall MA, Slater NJ, Begley CG, et al. Functional but abnormal adult erythropoiesis in the absence of the stem cell leukemia gene. Mol Cell Biol.2005;25:6355-6362.
12. Hall MA, Curtis DJ, Metcalf D, et al. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythro- poiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci USA. 2003;100:992-997.
13. McCormack MP, Hall MA, Schoenwaelder SM, et al. A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis. Blood. 2006;108:2248-2256.
14. Xu Z, Huang S, Chang LS, Agulnick AD, Brandt SJ. Identification of aTAL1 target gene reveals a positive role for the LIM domain-binding protein Ldb1 in erythroid gene expression and differentia-ion. Mol Cell Biol. 2003;23:7585-7599.
15. Lahlil R, Lecuyer E, Herblot S, Hoang T. SCL as-embles a multifactorial complex that determines glycophorin A expression. Mol Cell Biol. 2004;24:1439-1452.
16. Porcher C, Liao EC, FujiwaraY, Zon LI, Orkin SH. Specification of hematopoietic and vascular de-elopment by the bHLH transcription factor SCL without direct DNA binding. Development. 1999;126:4603-4615.
17. Keller G, Wall C, Fong AZ, HawleyTS, Hawley RG. Overexpression of HOX11 leads to the im-mortalization of embryonic precursors with both primitive and definitive hematopoietic potential.Blood. 1998;92:877-887.
18. Matys V, Fricke E, Geffers R, et al. (2003). TRANSFAC: transcriptional regulation, from pat-erns to profiles. Nucleic Acids Res. 2003;31:374-378.
19. Montell C, Courtois G, Eng C, Berk A. Complete transformation by adenovirus 2 requires both E1A proteins. Cell. 1984;36:951-961.
20. Lin Q, Lu J, Yanagisawa H, et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development. 1998;125:4565-4574.
21. Arnold MA, Kim Y, Czubryt MP, et al. MEF2C transcription factor controls chondrocyte hyper-trophy and bone development. Dev Cell. 2007;12:377-389.
22. Mikkola HK, Klintman J, Yang H, et al. Haemato-oietic stem cells retain long-term repopulating activity and multipotency in the absence of stem- cell leukaemia SCL/tal-1 gene. Nature. 2003;421:547-551.
23. Rhodes KE, Gekas C, Wang Y, et al. The emer-ence of hematopoietic stem cells is initiated in the placental vasculature in the absence of circulation. Cell Stem Cell. 2008;2:252-263.
24. Testa N, MolineuxG. Haemopoiesis: A Practical Approach. New York, NY: Oxford University Press; 1993.
25. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogen- esis by transcription factor MEF2C. Science.1997;276:1404-1407.
26. Bi W, Drake CJ, Schwarz JJ. The transcription factor MEF2C-null mouse exhibits complex vas-ular malformations and reduced cardiac expression of angiopoietin 1 and VEGF. Dev Biol. 1999;211:255-267.
27. Cumano A, Ferraz JC, Klaine M, Di Santo JP, Godin I. Intraembryonic, but not yolk sac hemato- poietic precursors, isolated before circulation, provide long-term multilineage reconstitution. Im-unity. 2001;15:477-485.
28. Godin I, Dieterlen-Lievre F, Cumano A. Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 days postcoitus. Pro catl Acad Sci U S A. 1995;92:773-777.
29. Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 1998;12:473-479.
30. Bi W, Drake CJ, Schwarz JJ. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expres-sion of angiopoietin 1 and VEGF. Dev Biol. 1999;211:255-267.
31. Stadtfeld M, Graf T. Assessing the role of hemato- poietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. De-velopment. 2005;132:203-213.
32. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595-621.
33. Igarashi H, Gregory SC, Yokota T, Sakaguchi N, Kincade PW. Transcription from the RAG1 locus
34. marks the earliest lymphocyte progenitors in bone marrow. Immunity. 2002;17:117-130.
35. Fuhrken PG, Chen C, Apostolidis PA, Wang M, Miller WM, Papoutsakis ET. Gene-ontology driven transcriptional analysis of CD34+-cell initi-ated megakaryocyte cultures identifies new tran- scriptional regulators of megakaryopoiesis. Physiol Genomics. 2008;22:159-169.
36. Molkentin JD, Black BL, Martin JF, Olson EN. Co-operative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell. 1995;83:1125-1136.
37. Molkentin JD, Olson EN. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci U S A. 1996;93:9366-9373.
38. Dodou E, Xu SM, Black BL. mef2c is activated directly by myogenic basic helix-loop-helix pro-teins during skeletal muscle development in vivo. Mech Dev. 2003;120:1021-1032.
39. Wang DZ, Valdez MR, McAnally J, Richardson J, Olson EN. The Mef2c gene is a direct transcrip- tional target of myogenic bHLH and MEF2 pro-teins during skeletal muscle development. Development. 2001;128:4623-4633.
40. Swanson BJ, Jack HM, Lyons GE. Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. Mol Immunol.1998;35:445-458.
41. Riley RL, Blomberg BB, Frasca D. B cells, E2A, and aging. Immunol Rev. 2005;205:30-47.
42. Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7-17.
43. Kirman I, Zhao K, Wang Y, Szabo P, Telford W, Weksler ME. Increased apoptosis of bone mar-row pre-B cells in old mice associated with their low number. Int Immunol. 1998;10:1385-1392.
44. Sherwood EM, Xu W, Riley RL. B cell precursors in senescent mice exhibit decreased recruitment into proliferative compartments and altered ex-pression of Bcl-2 family members. Mech Ageing Dev. 2003;124:147-153.
45. Wilker PR, Kohyama M, Sandau MM, et al. Tran-scription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimu-lation. Nat Immunol. 2008;9:603-612.
46. Schuler A, Schwieger M, Engelmann A, et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood. 2008;111:4532-4541.
47. Du Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer gene identification via onco- genic retrovirus-induced insertional mutagenesis. Blood. 2005;106:2498-2505.
48. Krivtsov AV, Twomey D, Feng Z, et al. Transfor-mation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442: 818-822.
49. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler HG, Macleod RA. MEF2C is activated by multiple mechanisms in a subset of T-acute lym- phoblastic leukemia cell lines. Leukemia. 2008;22:600-607.
50. Suzuki T, Shen H, Akagi K, et al. New genes in-volved in cancer identified by retroviral tagging. Nat Genet. 2002;32:166-174.